Update on Botulinum Toxin

Seminars in Cutaneous Medicine and Surgery

Volumn 26, Issue 4, 2007, Pages 196-202

  Flynn, Timothy Corcoran ^a,b  

^a Cary Skin Center   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; COLLAGEN; FILLER; HYALURONIC ACID; PLACEBO;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; ESTHETIC SURGERY; EYELID RECONSTRUCTION; FACE MUSCLE; FOOD AND DRUG ADMINISTRATION; HUMAN; LASER; LOWER EYELID; ORBICULARIS ORIS MUSCLE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHOTOPHOBIA; RHYTIDOPLASTY; WRINKLE;

ADJUVANTS, IMMUNOLOGIC; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; FACE; HUMANS; HYALURONIC ACID; METALLOENDOPEPTIDASES; NEUROMUSCULAR AGENTS; SKIN AGING;

EID: 41549104695     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2008.03.003     Document Type: Article

References (35)

1. Cox S.E., Finn J.C., Stetler L., et al. Development of the facial lines treatment satisfaction questionaire and initial results for botulinum toxin type A treated patients. Dermatol Surg 29 (2003) 444-449
2. Ascher B., Lowe N., Flynn T.C., et al. A practical guide to achieving successful outcomes with botulinum toxin type A. IMCAS Meeting, Paris 2002. J Cosmet Laser Ther 4 suppl 1 (2002) 1-6
3. Balikian R.V., and Zimbler M.S. Primary and adjunctive uses of botulinum toxin type A in the periorbital region. Facial Plast Surg Clin North Am 13 (2005) 583-590
4. Lowe N.J., Ascher B., Heckmann M., et al., Botox Facial Aesthetics Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Int Ophthalmol Clin 45 (2005) 123-131
5. Flynn T.C., Carruthers J., and Carruthers A. Botulinum A treatment of the lower eyelid improves infraorbital rhytids and widens the eye. Dermatol Surg 27 (2001) 703-708
6. Flynn T.C., Carruthers J., and Carruthers A. Botulinum toxin type A (Botox®) in the lower eyelids dose finding study. Dermatol Surg 29 (2003) 943-950
7. Klein A.W. Botox for the eyes and eyebrows. Dermatol Clin 22 (2004) 145-149
8. Tamura B.M. Standardization of muscle sites for BOTOX® injection in the frontal and glabellar regions. In: Hexel D., and Almerta A.T. (Eds). Cosmetic use of botulinum toxin (2002), AGE, Porto Alegra 145-148
9. Carruthers J., Fagren S., Matarasso S., and Botox Concencus Group. Concencus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconst Surg 114 suppl 6 (2004) 1S-22S
10. Carruthers A., and Carruthers J. Prospective, double-blind, randomized, parellel-group, dose-ranging study of botulinum toxin type A in men wth glabellar rhytids. Dermatol Surg 31 (2005) 1297-1303
11. Tamura B.M., Odo M.Y., Chang B., et al. Treatment of nasal wrinkles with botulinum toxin. Dermatol Surg 31 (2005) 271-275
12. de Maio M. The minimal approach: an innovation in facial cosmetic procedures. Aesthetic Plast Surg 28 (2004) 295-300
13. Bosniak S. Combination therapies: a nonsurgical approach to oculofacial rejuvenation. Ophthalmol Clin North Am 18 (2005) 215-225
14. Carruthers J.A., and Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 29 (2003) 802-809
15. Carruthers J.A., and Carruthers A. Facial sculpting and tissue augmentation. Dermatol Surg 31 (2005) 1604-1612
16. Beer K., Yohn M., and Closter J. A double-blinded, placebo-controlled study of BOTOX® for the treatment of subjects with chin rhytids. J Drugs Dermatol 4 (2005) 417-422
17. Semchyshyn N., and Sengelmann R.D. Botulinum toxin treatment of perioral rhytids. Dermatol Surg 29 (2003) 490-495
18. Carruthers J., and Carruthers A. Adjunctive botulinum toxin type A: fillers and light-based therapies. Int Ophthalmol Clin 45 (2005) 143-151
19. Shah G.M., and Kilmer S.L. Combined nonablative rejuvenation techniques. Dermatol Surg 31 (2005) 1206-1210 discussion 1210
20. Carruthers J., and Carruthers A. The effect of broadband light treatments alone and in combination with bilateral crow's feet botulinum toxin type A chemodenervation. Dermatol Surg 30 (2004) 355-356
21. Yamauchi P.S., Lask G., and Lowe N.J. Botgulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing. J Cosmet Laser Ther 6 (2004) 145-148
22. Semchyshyn N.L., and Kilmer S.L. Does laser inactivate botulinum toxin?. Dermatol Surg 31 (2005) 399-404
23. Ascher B., Zakine B., Kestemont P., et al. A multicenter, randomized, double-blid, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51 (2004) 223-233 [Erratum in J Am Acad Dermatol 52:156, 2005; Comment in J Am Acad Dermatol 53:364-365, 2005]
24. Lowe P.L., Patnaik R., and Lowe N.J. A comparison of two botulinum type A toxin preparations for the treatment of glabellar lies: double-blind, randomized, pilot study. Dermatol Surg 31 (2005) 1651-1654
25. Sadick N., and Sorhaindo L. The cosmetic use of botulinum toxin type B. Int Ophthalmol Clin 45 (2005) 153-161
26. Flynn T.C. Myobloc. Dermatol Clin 22 (2004) 207-211
27. Flynn T.C., and Clark R.E. Botulinum toxin type B (Myobloc) versus botulinum toxin type A (BOTOX®) frontalis study rate of onset and radium of diffuseion. Dermatol Surg 29 (2003) 519-522
28. Carruthers A, Carruthers J, Flynn TC, et al: Dose finding, safety, and tolerability study of Myobloc botulinum type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg, in press
29. Smith K.C., Comite S.L., Balasubramanian S., et al. Vibration anesthesia: a noninvasive method of reducing discomfort prior to dermatologic procedures. Dermatol Online J 10 (2004) 1 15
30. Beer K.R. Comparitive evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate to severe glabellar rhytids. Dermatol Surg 32 (2006) 184-192
31. Blumenfeld A.M., Dodick D.W., and Silberstein S.D. Botulinum neurotoxin for the treatment of migraine and other primary headaches disorders. Dermatol Clin 22 (2004) 167-175
32. Turk U., Ilham S., Alp R., et al. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharm 28 (2005) 161-162
33. Albani G., Petroni M.L., Mauro A., et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol 40 (2005) 833-835
34. Chuang Y.C., Chiang P.H., Huang C.C., et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66 (2005) 775-779
35. Maria G., Brisinda G., Civello I.M., et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62 (2003) 259-265